Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.
The choice of either induction or postremission therapy for adults with acute myeloid leukemia is still largely based on the "one size fits all" principle. Moreover, pretreatment prognostic parameters, especially chromosome and gene abnormalities, may fail in predicting individual patient outcome. Measurement of minimal residual disease (MRD) is nowadays recognized as a potential critical tool to assess the quality of response after chemotherapy and to plan postremission strategies that are, therefore, driven by the individual risk of relapse. PCR and multiparametric flow cytometry have become the most popular methods to investigate MRD because they have been established as sensitive and specific enough to allow MRD to be studied serially. In the present review, we examine the evidence supporting the appropriateness of incorporating MRD detection into the AML risk assessment process. A comprehensive prognostic algorithm, generated by combining pretreatment cytogenetics/genetics and posttreatment MRD determination, should promote advances in development of personalized therapeutic approaches.
Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy.
Francesco
F
Buccisano
Luca
L
Maurillo
Maria Ilaria
MI
Del Principe
Giovanni
G
Del Poeta
Giuseppe
G
Sconocchia
Francesco
F
Lo-Coco
William
W
Arcese
Sergio
S
Amadori
Adriano
A
Venditti
D000328:Adult; D002986:Clinical Trials as Topic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000628:therapy*; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000209:etiology*; D011379:Prognosis